Geode Capital Management, LLC Clene Inc. Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Clene Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 946,532 shares of CLNN stock, worth $340,751. This represents 0.0% of its overall portfolio holdings.

Number of Shares

946,532

Previous 611,879 54.69%

Holding current value

$340,751

Previous $183,000 122.4%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$0.28 - $0.53 $93,702 - $177,366	334,653 Added 54.69%	946,532 $407,000
Q4 2023 Feb 13, 2024	BUY	$0.26 - $0.55 $6 - $13	25 Added 0.0%	611,879 $183,000
Q3 2023 Nov 13, 2023	BUY	$0.46 - $0.87 $136,758 - $258,651	297,300 Added 94.51%	611,854 $305,000
Q1 2023 May 15, 2023	BUY	$0.95 - $1.62 $79,561 - $135,673	83,749 Added 36.29%	314,554 $355,000
Q4 2022 Feb 13, 2023	BUY	$0.92 - $1.11 $8,844 - $10,671	9,614 Added 4.35%	230,805 $230,000

Q3 2022 Nov 14, 2022	SELL	$0.33 - $4.83 $3,217 - $47,087	-9,749 Reduced 4.22%	221,191 $619,000
Q2 2022 Aug 12, 2022	SELL	$2.1 - $4.12 $323,454 - $634,587	-154,026 Reduced 40.01%	230,940 $581,000
Q1 2022 May 13, 2022	SELL	$2.42 - $4.42 $6,413 - $11,713	-2,650 Reduced 0.68%	384,966 $1.52 Million
Q4 2021 Feb 11, 2022	SELL	$3.95 - $7.53 $71,577 - $136,451	-18,121 Reduced 4.47%	387,616 $1.59 Million
Q3 2021 Nov 12, 2021	BUY	$6.83 - $13.58 $22,825 - $45,384	3,342 Added 0.83%	405,737 $2.77 Million
Q2 2021 Aug 13, 2021	BUY	$6.98 - $13.33 $1.27 Million - $2.43 Million	182,040 Added 82.61%	402,395 $4.52 Million
Q1 2021 May 12, 2021	BUY	$6.39 - $16.3 $1.41 Million - $3.59 Million	220,355 New	220,355 $2.82 Million

Others Institutions Holding CLNN

# of Institutions

Shares Held

7.44M

Call Options Held

48.1K

Put Options Held

160K

View Full List

About Clene Inc.

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $22.9M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

More about CLNN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Clene Inc. Transaction History